Dr
No verificado

Drug Farm

Sobre qué escribimos

BiotecnologíaCienciaFarmacéuticaMedicina - VariosSalud
22/10/2026
Ciencia
Cardiología
Biotecnología
Farmacéutica
Salud
VIH, SIDA y enfermedades autoinmunes
Eventos
Ferias y Congresos
Industria
Drug Farm Announces Positive Preclinical Findings Demonstrating DF-003 Reduces Kidney Inflammation and Fibrosis at ASN Kidney Week 2026
1.00
13/07/2026
Técnica
Finanzas
Biotecnología
Medicina - Varios
Asociaciones/Profesionales
Farmacéutica
Salud
Drug Farm Completes First Closing of $55 Million Series D Financing to Advance Clinical and Preclinical Development Pipeline
1.00
07/05/2026
Industria
Eventos
Ciencia
VIH, SIDA y enfermedades autoinmunes
Biotecnología
Medicina - Varios
Cardiología
Farmacéutica
Salud
Óptica
Drug Farm to Present Ophthalmologic and CNS Findings from Phase 1b Study of First-in-Class ALPK1 Inhibitor DF-003 in ROSAH Syndrome at ARVO 2026
1.00
17/04/2026
Eventos
Industria
Sanidad
Ciencia
Farmacéutica
Óptica
VIH, SIDA y enfermedades autoinmunes
Biotecnología
Medicina - Varios
Cardiología
Salud
Drug Farm to Present Positive Phase 1b Data for First-in-Class ALPK1 Inhibitor DF-003 in ROSAH Syndrome at IMMUNOLOGY2026™
1.00
26/03/2026
Industria
Cardiología
Biotecnología
Higiene alimentaria
Salud
Farmacéutica
Óptica
Ciencia
VIH, SIDA y enfermedades autoinmunes
Medicina - Varios
Drug Farm Announces U.S. FDA Orphan Drug Designation for DF-003 for the Treatment of ROSAH Syndrome
1.00
05/03/2026
Industria
Ciencia
VIH, SIDA y enfermedades autoinmunes
Higiene alimentaria
Biotecnología
Medicina - Varios
Cardiología
Farmacéutica
Salud
Drug Farm Announces FDA Acceptance of DF-003 into Rare Disease Evidence Principles Process for ROSAH Syndrome
1.00
27/01/2026
Cardiología
Biotecnología
Higiene alimentaria
Salud
Farmacéutica
Óptica
Ciencia
VIH, SIDA y enfermedades autoinmunes
Medicina - Varios
Industria
Drug Farm Announces FDA Fast Track Designation for First-in-Class ALPK1 Inhibitor DF-003 for the Treatment of ROSAH Syndrome
1.00
23/09/2025
Mercado laboral
Industria
Ciencia
VIH, SIDA y enfermedades autoinmunes
Biotecnología
Cardiología
Salud
Farmacéutica
Oncología
Drug Farm Announces Agreement with Cincinnati Children’s Hospital Medical Center to Explore ALPK1 Inhibitor, DF-003 as a Potential Treatment for Heart Disease and Blood Cancers Driven by Clonal Hematopoiesis
1.00
09/09/2025
Ciencia
VIH, SIDA y enfermedades autoinmunes
Biotecnología
Medicina - Varios
Cardiología
Salud
Farmacéutica
Industria
Drug Farm Announces Publication in Nature Communications Describing the Discovery and Preclinical Characterization of First-in-Class ALPK1 inhibitor, DF-003
1.00

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0